AN1
Click for more information
0.00% 0.8¢ anagenics limited

Lyramid has the exclusive worldwide licence to commercialise up...

  1. tsuba
    1,276 Posts.
    lightbulb Created with Sketch. 125
    clock Created with Sketch.
    30/09/21
    09:02
    Post #: 56453321
    Lyramid has the exclusive worldwide licence to commercialise up to 37 patents related to Midkine-based therapies for the treatment of COVID-19 patients, cancer, autoimmune disorders and chronic kidney disease ("Midkine-Based Therapies")

    CDY Price at posting: 5.6¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 5  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

AVA Ava Risk Group expands US presence with A$0.7M Substation Deal
right-arrow Created with Sketch.
ITM iTech lifts MRE at Eyre Peninsula Graphite Project by 300%
right-arrow Created with Sketch.
LRV Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%
right-arrow Created with Sketch.
EX1 Tryptamine Therapeutics completes maiden dosing of IV psilocin – a global first
right-arrow Created with Sketch.
BIO Biome posts record sales revenue of $13M in FY24 – up 80% vs pcp and higher than forecast
right-arrow Created with Sketch.
NEWS Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker
right-arrow Created with Sketch.
watchlist Created with Sketch. Add AN1 (ASX) to my watchlist
(20min delay)
Last
0.8¢ 		Change
0.000(0.00%) 		Mkt cap ! $3.690M
Open High Low Value Volume
0.8¢ 0.8¢ 0.8¢ $4.704K 588K

Buyers (Bids)

No. Vol. Price($)
1 697002 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 340000 1
View Market Depth
Last trade - 15.07pm 03/07/2024 (20 minute delay) ?
AN1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.